Supernus Pharmaceuticals (SUPN) Invested Capital (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Invested Capital data on file, last reported at $1.1 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at $1.1 billion, up 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 1.52% YoY), and the FY2025 annual result was $1.1 billion, up 0.89% from the prior year.
• Invested Capital declined to $1.1 billion in Q1 2026 per SUPN's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Invested Capital peaked at $1.3 billion in Q3 2022 and troughed at $875.3 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $1.1 billion in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2023: Invested Capital jumped 53.54% in 2022, then dropped 24.29% in 2023.
• A 5-year view of Invested Capital shows it stood at $907.3 million in 2022, then gained by 7.3% to $973.6 million in 2023, then increased by 11.25% to $1.1 billion in 2024, then advanced by 0.89% to $1.1 billion in 2025, then declined by 1.46% to $1.1 billion in 2026.
• Business Quant data shows SUPN's Invested Capital at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.